dsRNA is a widespread problematic impurity that can cause adverse reactions to mRNA therapies and is currently removed or mitigated using specialized purification instruments that reduce yields and increase manufacturing costs.
The recently filed provisional patents are foundational to Applied DNA's recently launched Linea IVT platform that enables next-generation mRNA production by leveraging the unique attributes of the Company's PCR-based LinearDNA platform resulting in a simplified mRNA production workflow with reduced dsRNA contamination. The Linea IVT platform combines cell-free, enzymatically produced linearDNA IVT templates with the Company's proprietary Linea RNA polymerase to deliver multiple advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of dsRNA contamination resulting in higher target mRNA yields and, 3) the delivery of IVT templates in as little as 14 days for milligram scale and 30 days for gram scale.
'These provisional patent applications are the first step in protecting our valuable intellectual property that empowers our differentiated approach to mRNA production,' stated Dr.
About
Forward-Looking Statements
The statements made by Applied DNA in this press release may be 'forward-looking' in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations and are based on assumptions, and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from the Linea IVT platform, the unknown patentability of the subject matter claimed in the provisional patent applications, limited market acceptance for its supply chain security products and services, the declining demand for Applied DNA's COVID-19 testing services, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's
Contact:
Tel: 631-912-6454
Email: clay.shorrock@adnas.com
Web: www.adnas.com
(C) 2023 Electronic News Publishing, source